|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Drug Monitoring, Antipsychotics, with Confirmation, Serum
Test Code94529
CPT Codes
80307
Includes
Aripiprazole, Chlorpromazine, Clozapine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Olanzapine, Quetiapine, Risperidone, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone
If screening drug class result is equal to or greater than the cutoff, then confirmation testing will be performed at an additional charge (CPT code(s): 80342 or 80343 or 80344).
If screening drug class result is equal to or greater than the cutoff, then confirmation testing will be performed at an additional charge (CPT code(s): 80342 or 80343 or 80344).
Preferred Specimen
1 mL serum collected in a red-top tube (no gel)
Minimum Volume
0.5 mL
Other Acceptable Specimens
Plasma collected in: EDTA (lavender-top) tube, sodium heparin (green-top) tube, or ACD-A (yellow-top) tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 5 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Serum Separator Tube (SST®)
Methodology
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues, Thurs, Sat; Report available: 1-4 days
Reference Range
See Laboratory Report
Clinical Significance
Antipsychotic (AP) drugs are widely prescribed for the treatment of schizophrenia and psychosis. The so-called first generation or typical APs were developed in the 1950s and show severe side-effects such as extrapyramidal symptoms due to their pharmacological action on d2 and d4 receptors. As a measure of reducing these severe side-effects, a range of ‘second generation’ APs were developed. These newer generation drugs act considerably less on d2 and d4 receptors and therefore exhibit less extrapyramidal side-effects.
Over the last decade, the prescription rate of APs (more notably second generation) has increased worldwide, [1-3] especially among young adults and children [1-4]. However, second generation APs are not entirely free of side-effects. Irrespective of their generation, it has been shown that these drugs can increase the risk of sudden cardiac death with studies showing that the risk of sudden cardiac death is increased threefold among patients treated with APs.
Over the last decade, the prescription rate of APs (more notably second generation) has increased worldwide, [1-3] especially among young adults and children [1-4]. However, second generation APs are not entirely free of side-effects. Irrespective of their generation, it has been shown that these drugs can increase the risk of sudden cardiac death with studies showing that the risk of sudden cardiac death is increased threefold among patients treated with APs.
